Skip to content
Tanabe Pharma
-
Tolerance Bio licenses Tanabe Pharma’s anti IL 33 antibody for global development
TLB 33 is a human immunoglobulin G1 monoclonal antibody designed to bind to and neutralise interleukin 33, an immune signalling protein.
-
LEO Pharma to acquire Tanabe’s Dersimelagon for rare photosensitivity disorders
Under the agreement, LEO will pay up to US$435 million in upfront and near-term milestone payments for global rights to dersimelagon.
-
Tanabe Pharma sells manufacturing unit and 17 off-patent drugs to Towa Pharmaceutical
The transaction, announced on July 3, includes Tanabe Pharma Factory’s production facilities in Onoda and Yoshitomi.